|
Study of Talabostat in Advanced Melanoma Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Study of Talabostat in Advanced Melanoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of Talabostat in Advanced Melanoma Clinical research trials and Study of Talabostat in Advanced Melanoma healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Study of Talabostat in Advanced Melanoma. Study of Talabostat in Advanced Melanoma Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Study of Talabostat in Advanced Melanoma clinical trial. Human subjects often obtain the finest healthcare possible for their Study of Talabostat in Advanced Melanoma condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Talabostat in Advanced Melanoma  Study of Talabostat in Advanced Melanoma
Study of Talabostat in Advanced Melanoma
For Condition: Melanoma,Skin Cancer
Status: Recruiting
Sponsor(s): Point Therapeutics ,
Synopsis: The purpose of this study is to assess the antitumor activity and safety of talabostat in patients with metastatic melanoma.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Histologically or cytologically confirmed melanoma that is metastatic (unresectable Stage IV per AJCC 2002) - Patients with measurable disease defined as at least one measurable index lesion with clearly defined margins - ECOG Performance Status of 0, 1, or 2 - Expected survival 12 weeks - Written informed consent Exclusion Criteria: - More than 1 prior chemotherapy or biotherapy regimen for Stage IV melanoma - Radiation therapy to >50% of the bone marrow. Patients must not have had prior radiotherapy to index lesions unless they have clearly progressive disease in this site or there is measurable disease outside the area of prior radiation. - Clinically significant laboratory abnormalities - CNS metastases - Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix - The need for chronic (i.e., >7 days) oral or intravenous corticosteroid therapy - Any comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this protocol - Patients who are within 30 days of chemotherapy, radiation therapy, immunotherapy, or other investigational medication for melanoma. Patients must have recovered from all of the side effects of treatment in order to be enrolled. - Pregnant or lactating women.
Total Enrollment:
Location and Contact Information:
Dartmouth-Hitchcock Medical Center *Not yet recruiting*
Lebanon, New Hampshire, 03756-001
United States
Not yet recruiting
University of Michigan *Not yet recruiting*
Ann Arbor, Michigan, 48109-0473
United States
Not yet recruiting
Emory University/Winship Cancer Institute *Not yet recruiting*
Atlanta, Georgia, 30322-1013
United States
Not yet recruiting
University of Chicago *Not yet recruiting*
Chicago, Illinois, 60637
United States
Not yet recruiting
Mary Crowley Medical Research Center *Recruiting*
Dallas, Texas, 75246
United States
Recruiting
Additional Information:
Study ID Numbers: PTH-301;
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00083239
Other Melanoma Studies:
1. Surgery vs. Chemotherapy in Patients with Stage IV Melanoma
2. A Phase II study of PI-88 in Patients with Advanced Melanoma
3. Thalidomide and Dacarbazine for Metastatic Melanoma
4. Comparison Study of MDX-010 (CTLA-4) Alone and Combined with DTIC in the Treatment of Metastatic Melanoma
5. Flt3L and CD40L to Treat Metastatic Melanoma and Kidney Cancer
Related Studies:
Other Melanoma Clinical Trials
Other Georgia Clinical Trials
Other Atlanta Clinical Trials
Study of Talabostat in Advanced Melanoma
|
|
|
|
|
|
|
|
